世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  遺伝子  >  多発性嚢胞腎 - パイプラインレビュー 2016年下半期

多発性嚢胞腎 - パイプラインレビュー 2016年下半期
Polycystic Kidney Disease - Pipeline Review, H2 2016

レポートタイトル 多発性嚢胞腎 - パイプラインレビュー 2016年下半期
出版社名 Global Markets Direct
発刊日 2016-10-29
体裁 PDF / 87 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 遺伝子
疾患名 多発性嚢胞腎
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Polycystic Kidney Disease Overview 8
Therapeutics Development 9
Pipeline Products for Polycystic Kidney Disease - Overview 9
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 10
Polycystic Kidney Disease - Therapeutics under Development by Companies 11
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 12
Polycystic Kidney Disease - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Polycystic Kidney Disease - Products under Development by Companies 16
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 17
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 18
Angion Biomedica Corp. 18
Aptevo Therapeutics Inc 19
DiscoveryBiomed, Inc. 20
Endocyte, Inc. 21
IC-MedTech, Inc. 22
Ipsen S.A. 23
Kadmon Corporation, LLC 24
ManRos Therapeutics 25
Metabolic Solutions Development Company, LLC 26
NovaTarg Therapeutics, Inc 27
Otsuka Holdings Co., Ltd. 28
XORTX Pharma Corp. 29
Polycystic Kidney Disease - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(ascorbic acid + menadione) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ANG-3070 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
CIM-2 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CR-8 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
DBM-43H11 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Drugs for Polycystic Kidney Disease - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
EC-0371 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
JP-153 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
lanreotide acetate - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
menadione sodium bisulfite - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
MSDC-0160 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MSDC-0602 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
oxypurinol - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
pyrimethamine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
STA-2842 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
tesevatinib tosylate - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
TNFR x TWEAKR - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
tolvaptan - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Polycystic Kidney Disease - Dormant Projects 73
Polycystic Kidney Disease - Discontinued Products 74
Polycystic Kidney Disease - Product Development Milestones 75
Featured News & Press Releases 75
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 75
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 76
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 76
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases 77
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 78
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 79
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 79
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide 81
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease 82
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 82
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease 83
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease 83
Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease 84
Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease 84
Aug 05, 2013: U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical’s Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Figures
Number of Products under Development for Polycystic Kidney Disease, H2 2016 9
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Top 10 Targets, H2 2016 32
Number of Products by Stage and Top 10 Targets, H2 2016 32
Number of Products by Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Routes of Administration, H2 2016 36
Number of Products by Stage and Routes of Administration, H2 2016 36
Number of Products by Molecule Types, H2 2016 38
Number of Products by Stage and Molecule Types, H2 2016 38

List of Tables
Number of Products under Development for Polycystic Kidney Disease, H2 2016 9
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp., H2 2016 18
Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2016 19
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H2 2016 20
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H2 2016 21
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H2 2016 22
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H2 2016 23
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H2 2016 24
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2016 25
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016 26
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 27
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 28
Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Polycystic Kidney Disease - Dormant Projects, H2 2016 73
Polycystic Kidney Disease - Discontinued Products, H2 2016 74
Loading....